NCT03059134View on ClinicalTrials.gov

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

PHASE3CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

April 28, 2015

Primary Completion Date

April 27, 2016

Study Completion Date

April 27, 2016

Conditions

Urinary IncontinenceOveractive Bladder Syndrome

Interventions

DRUG

Mirabegron 25mg

We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.

All Listed Sponsors

lead

Buddhist Tzu Chi General Hospital

OTHER

NCT03059134 - Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan | Biotech Hunter | Biotech Hunter